• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-1MEF filed by Aptevo Therapeutics Inc.

    6/18/25 2:30:31 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email
    S-1MEF 1 apvo-2025-s1mef_-_june_o.htm S-1MEF S-1MEF

    As filed with the Securities and Exchange Commission on June 18, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    APTEVO THERAPEUTICS INC.

    (Exact Name of Registrant as Specified in Its Charter)

    Delaware

    2834

    81-1567056

    (State or Other Jurisdiction of

    Incorporation or Organization)

    (Primary Standard Industrial

    Classification Code Number)

    (I.R.S. Employer

    Identification Number)

    2401 4th Avenue, Suite 1050

    Seattle, Washington, 98121

    (206) 838-0500

    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

    Marvin L. White

    President and Chief Executive Officer

    Aptevo Therapeutics Inc.

    2401 4th Avenue, Suite 1050

    Seattle, Washington, 98121

    (206) 838-0500

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

    Copies to:

    Sean M. Donahue

    Paul Hastings LLP

    2050 M Street, NW

    Washington, DC 20036

    (202) 551-1704

     SoYoung Kwon

    Senior Vice President and General Counsel

    Aptevo Therapeutics Inc.

    2401 4th Avenue, Suite 1050

    Seattle, Washington, 98121

    (206) 838-0500

    Charles E. Phillips

    Ellenoff Grossman & Schole LLP

    1345 Avenue of the Americas

    New York, NY 10105

    (212) 370-1300

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-288061)

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large Accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.


     

    EXPLANATORY NOTE

    This 462(b) Registration Statement relates to the reasonable best efforts public offering of securities (the “Offering”) contemplated by the Registration Statement on Form S-1 (File No. 333-288061), which was initially filed with the United States Securities and Exchange Commission (the “SEC”) on June 16, 2025, and which was declared effective by the SEC on June 18, 2025 (the “Prior Registration Statement”).

    This Registration Statement on Form S-1 is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the purposes of registering additional securities of the same class as were included in the Prior Registration Statement, representing an increase in the maximum aggregate offering price by $67,500, which includes $11,250 worth of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and/or prefunded warrants to purchase $11,250 worth of shares of Common Stock to be issued to the investors and common warrants to purchase up to $56,250 worth of Common Stock.

    The additional securities that are being registered for sale are in an amount and at a price that together represents no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 to the Prior Registration Statement.

    The contents of the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference.

    The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

     


     

    EXHIBIT INDEX

    Exhibit No.

    Exhibit Description

    5.1

    Opinion of Paul Hastings LLP.

    23.1

    Consent of Moss Adams LLP, Independent Registered Public Accounting Firm.

    23.2

    Consent of Paul Hastings LLP (included in Exhibit 5.1).

    24.1*

    Power of Attorney.

    107

    Filing Fee Table.

     

    *

    Previously filed on the signature page to the Prior Registration Statement and incorporated by reference herein.

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Seattle, State of Washington, on June 18, 2025.

    Aptevo Therapeutics Inc.

    Date: June 18, 2025

    By:

    /s/ Marvin L. White

    Marvin L. White

    President and Chief Executive Officer

    Pursuant to the requirements of the Securities Act of 1933, as amended this registration statement has been signed by the following persons in the capacities indicated on the 18th day of June, 2025.

     


     

    Signatures

    Title

    /s/ Marvin L. White

     President, Chief Executive Officer and Director

    Marvin L. White

     (Principal Executive Officer)

    *

    Senior Vice President and Chief Financial Officer

    Daphne Taylor

    (Principal Financial and Accounting Officer)

    *

    Chairman of the Board of Directors

    John E. Niederhuber, M.D.

    *

     Director

    Daniel J. Abdun-Nabi

    *

     Director

    Grady Grant, III

    *

     Director

    Zsolt Harsanyi, Ph. D.

    *

     Director

    Barbara Lopez Kunz

    * /s/ Marvin L. White Attorney-in-Fact

     

     


    Get the next $APVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

    Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today.DetailsSession Title: Bi and Multispecific BiologicsTalk Title: Modular Multispecific

    1/15/25 8:00:00 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

    SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common s

    12/12/24 12:50:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

    Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual d

    12/12/24 9:00:00 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    SEC Filings

    View All

    Aptevo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

    2/3/26 8:15:25 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Aptevo Therapeutics Inc.

    EFFECT - Aptevo Therapeutics Inc. (0001671584) (Filer)

    2/2/26 12:15:32 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by Aptevo Therapeutics Inc.

    424B4 - Aptevo Therapeutics Inc. (0001671584) (Filer)

    1/30/26 5:02:47 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Bank Of America Corp /De/

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    10/3/25 2:19:07 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Bank Of America Corp /De/ claimed ownership of 27 shares (SEC Form 3)

    3 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    10/3/25 1:59:55 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Aptevo Therapeutics with a new price target

    Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously

    5/28/21 8:33:45 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Leadership Updates

    Live Leadership Updates

    View All

    BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

    NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

    11/2/21 9:00:00 AM ET
    $AMGN
    $APVO
    $BCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Specialty Insurers

    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

    SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/14/24 3:45:38 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aptevo Therapeutics Inc.

    SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/8/24 2:57:35 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aptevo Therapeutics Inc.

    SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

    2/14/24 3:24:02 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care